With more than 20 years of experience in the pharmaceutical industry, Dr. Dominique Costantini has overseen many therapeutic innovations in the international framework of oncology. Throughout her career, she held a of management positions within HMR (now Sanofi) where she led medico-marketing activities to commercialize products (notably in immunology, endocrinology, infectious illnesses and oncology). While there, Ms. Costantini also participated in the development of various medicines, from conception to product approval and commercialization.
In 1997, Ms.Costantini founded BioAlliance Pharma, where she held the position of Chief Executive Officer until 2011 and during which time, she led BioAlliance Pharma’s IPO on Euronext (2005). BioAlliance Pharma originated Livatag®, an anti-cancer nanotechnology in primary liver cancer, currently in Phase 3 (in Europe and the USA). In her experience, Ms. Costantini has been the source of many international industrial partnerships (Europe, USA, China, Japan and Korea). To date, BioAlliance Pharma (renamed Onxeo in 2014) is the only French biotechnology company to have two FDA drug approvals.
In 2012, Ms. Costantini co-founded and led OSE Pharma as Chief Executive Officer.
Dr. Dominique Costantini is a doctor (Paris V university), who specialises in immunology.
Maryvonne Hiance specializes in nuclear science and served, for 14 years, as manager of neutron studies at FRAMATOME (Areva). Over a 20 year period, she held the position of General Manager at innovative biotechnology companies including SangStat Atlantic, DrugAbuse Sciences and TcLand. Ms Hiance also founded and served as General Manager of Strategic Ventures, a consulting company providing support to technological companies.
Ms. Hiance has been a member of the French Strategic Council for Innovation and has served as Advisor to the French SMEs and Industry Ministry.
In 2008, Ms. Hiance co-founded and served as Chairman of the Board of Effimune, a biotechnology company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology.
Vice Chairman of the Board of OSE Immunotherapeutics, Ms Hiance also serves as Strategy Advisor to the company’s Management.
Ms. Hiance holds an Engineering Degree from the « Ecole Polytechnique Feminine », Paris, and a Nuclear Engineering Degree from the « Institut des Sciences et Techniques », Grenoble.
Alexis Peyroles has more than 15 years of management and financial control experience, having served in related positions, internationally. Alexis Peyroles joined Sanofi-Aventis in 1996, working first as Financial Controller in Japan before becoming Head of financial control for the Baltic states. He was subsequently named Head of activities for Business Development in Eastern Europe. In 2005, he joined the Guerbet group (a leader in the field of contrast products, especially in medical imaging) as Financial Control Manager and in 2009, became Chief Executive Officer for Latin America, based in Brazil.
As soon as 2013, Alexis Peyroles has been involved in OSE Pharma and served as Chief Financial Officer and was in charge of Business Development. Upon the merger of OSE Pharma with Effimune in May 2016, he was appointed Chief Operating Officer of OSE Immunotherapeutics, in charge of Finance, Business Development and Operations.
Alexis Peyroles graduated from EDHEC Business School and holds an Imperial Executive MBA.
Bernard Vanhove has extensive international scientific experience, in particular at the Research Institute of Sandoz in Vienna (Austria). He serves as Research Director at the « Centre National de Recherche Scientifique » (CNRS, French National Scientific Research Institute), the « Institut National de la Santé et Recherche Médicale » (INSERM, National Institute for Health and Medical Research) and the « Institut de Transplantation-Immunologie-Urologie » (ITUN, Institute of Transplantation in Immuno-urology). He has also conducted research activities at the « Centre Européen des Sciences de la Transplantation et Immunothérapie » (CESTI, European Center for Transplantation and Immunotherapy Sciences).
In 2013, Bernard Vanhove was awarded a Prize from « France Transplant » for his pharmacological preclinical studies evaluating the efficacy of FR104 (a pegylated monovalent anti-CD28 Fab antibody) in immunology. Moreover, he was the coordinator of the European FP7 network « TRIAD » (Tolerance Restoration in Autoimmune Diseases) in autoimmune diseases. He is the author of more than 80 international publications in the area of immune restoration.
In 2008, Bernard Vanhove co-founded Effimune, becoming Chief Executive Officer in July 2014. Upon the merger of Effimune with OSE Pharma in May 2016, he was appointed Chief Operating Officer of OSE Immunotherapeutics, in charge of R&D and International Scientific Collaborations.
Bernard Vanhove holds a Ph.D. in Immunology (from the Louvain University, Belgium).